PT -期刊文章AU -埃比尼泽巨人盟Ilise Lombardo AU -卡洛琳朱盟-班斯特恩非盟-劳伦斯Friedhoff TI -评估依赖的痴呆ADCS-ADL依赖规模的使用一个转换算法的双盲安慰剂对照试验Intepirdine (rvt - 101) (P3.088) DP - 2017年4月18日TA -神经病学PG - P3.088 VI - 88 IP - 16补充4099 - //www.ez-admanager.com/content/88/16_Supplement/P3.088.short 4100 - //www.ez-admanager.com/content/88/16_Supplement/P3.088.full所以首页Neurology2017 4月18日;88 AB -目的:估计intepirdine依赖在阿尔茨海默氏症的影响。背景:阿尔茨海默病(AD)试验通常集中在认知和功能结果来评估药物疗效。然而,使用依赖规模增加了兴趣,13项范围,评估患者需求程度的援助。依赖规模捕捉认知的结合,功能和行为变化,发生在广告和相关成本。我们检查了依赖的潜在后果的研究intepirdine (rvt - 101),一个口头管理,被调查5-HT6受体拮抗剂治疗轻度到中度阿尔茨海默病(AD)和路易体痴呆。设计/方法:数据取自双盲,安慰剂对照试验的intepirdine受试者接受稳定的多奈哌齐治疗轻度至中度AD和随机获得35毫克intepirdine intepirdine 15毫克或安慰剂。安慰剂和35毫克的数据都包含在这一分析。ADCS-ADL是转化为依赖级别(DL)使用发表算法分配DL基于IADL模式/ BADL损伤比较DL发展积极与安慰剂治疗武器。结果:基线DL在治疗组相似。在基线DL和ADCS-ADL之间的相关性为0.448(0.360访问,术中;。)。DL不寻常的比例在DL(增加一个或多个代表恶化ADL水平/大保健需求)都高于安慰剂组随访评估和治疗差异随时间增长达到统计学意义在36周,48。结论:附加疗法intepirdine估计减少了进程的DL / 48周,表明病人花更多的时间在减少阶段的依赖广告。 Because the scale is readily translated into cost and the need for full-time care, it is a potentially powerful approach for quantifying the impact and value of a therapeutic effect.Study Supported by: Axovant SciencesDisclosure: Dr. Asare has received personal compensation for activities with Axovant Sciences as an employee. Dr. Lombardo has received personal compensation for activities with Axovant Sciences Inc. as an employee. Dr. Zhu has received personal compensation for activities with Axovant and Xcenda as a consultant. Dr. Stern has received personal compensation for activities with Takeda, Axovant, and Eli Lilly and Company as an advisor and/or consultant. Dr. Stern has received license fees from Columbia. Dr. Stern has received research support from Axovant, Piramal and the California Walnut Commission. Dr. Friedhoff has received personal compensation for activities with Axovant Sciences Inc and Roivant Sciences Inc. as an employee.